Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery ) Development Candidates for the Treatment of Alzheimer's Disease

  • ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option under its license agreement with JCR Pharmaceuticals
  • EBD technology represents the only anti-amyloid oligomer program combining a validated blood-brain barrier-penetrating technology with a therapeutic antibody tested in the clinic
  • Acumen's EBD candidates are designed to achieve higher brain penetration with potential for improved safety compared to native antibodies and delivered in a stable, low volume subcutaneous administration format
  • Investigational New Drug (IND)-enabling activities are ongoing to support IND submission in mid-2027

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced the nomination of two development candidates in its Enhanced Brain Delivery (EBD) program as treatments for AD. Building on robust preclinical data from both in vitro and in vivo studies, the Company has exercised its option with JCR Pharmaceuticals (JCR) as part of its previously signed agreement and will advance both candidates combining Acumen's AβO-selective antibody expertise and JCR's validated transferrin-receptor-targeting blood-brain barrier-penetrating technology, termed J-Brain Cargo®. By selecting these two candidates, the Company is expanding its optionality by nominating a bispecific antibody derived from sabirnetug as well as one based on a novel, next generation AβO-selective antibody with differentiated properties, known as ACU234.

"The nomination of these candidates marks an important step forward in our effort to bring meaningful new treatment options to patients with Alzheimer's disease," said Jim Doherty, President and Chief Development Officer of Acumen. "By leveraging JCR's J-Brain Cargo® alongside our oligomer-selective antibodies, we're building a differentiated portfolio of bispecific antibodies designed to overcome the challenges of delivering therapeutics across the blood-brain barrier for the treatment of this devastating disease. We are advancing IND-enabling activities toward a mid-2027 IND submission and are excited about the potential to offer patients and caregivers more effective and convenient therapeutic options."

As announced in a March 2026 press release, preclinical studies demonstrated consistent and predictive results across multiple models, including murine and non-human primate (NHP) studies. The candidates achieved significantly enhanced brain penetration, with antibody levels 14-40x higher in NHPs than native antibodies at 24 hours. Assessment of a panel of hematology endpoints in NHPs suggested a low risk of anemia, and there were no adverse events observed across all tested species. Additionally, the EBD development candidates exhibited favorable stability and plasma PK profiles in NHPs following subcutaneous (SC) administration, supporting their suitability for SC dosing in patients. Further information will be presented at a future medical meeting.

J-Brain Cargo® technology is JCR's proprietary drug delivery system that efficiently delivers drugs to target tissues, including the central nervous system, through receptor-mediated transcytosis. It is applicable to various modalities including antibodies, enzymes, oligonucleotides, lipid nanoparticles, gene and cell therapy, peptides, and decoy receptors. Acumen's research on EBD technology is part of an ongoing collaboration between Acumen and JCR announced in July 2025.

About Sabirnetug (ACU193)

Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble AβOs, which are a highly toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function, and induce neurodegeneration. By selectively targeting toxic soluble AβOs, sabirnetug aims to address the hypothesis that soluble AβOs are an early and persistent underlying cause of the neurodegenerative process in AD. Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD.  

About ALTITUDE-AD (Phase 2)

Initiated in 2024, ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease. The study has enrolled 542 individuals with early Alzheimer's disease (mild cognitive impairment or mild dementia due to AD) at multiple investigative sites located in the United States, Canada, the European Union and the United Kingdom. Topline results are expected in late 2026. More information can be found on www.clinicaltrials.gov, NCT identifier NCT06335173.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic AD, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is investigating a subcutaneous formulation of sabirnetug using Halozyme's proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery™ (EBD™)-enabled therapy for Alzheimer's disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.

About the J-Brain Cargo® Platform Technology

JCR Pharmaceuticals has developed a proprietary blood-brain barrier (BBB)-penetrating technology, J-Brain Cargo®, to bring biotherapeutics into the central nervous system (CNS). The first drug developed based on this technology is IZCARGO™ (INN: pabinafusp alfa) and is approved in Japan for the treatment of a lysosomal storage disorder.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. JCR continues to build upon our 50-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. JCR's innovative therapies address conditions like growth disorder, MPS II, Fabry disease, acute graft-versus-host disease, and renal anemia. JCR is also developing treatments for rare diseases like MPS I, MPS II, MPS IIIA and B, and more. For more information, visit https://jcrpharm.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as "believes," "expects," "anticipates," "could," "should," "would," "seeks," "aims," "plans," "potential," "will," "milestone" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen's business, the therapeutic potential of Acumen's product candidate, sabirnetug (ACU193) and the potential of two development candidates in Acumen's Enhanced Brain Delivery (EBD) program. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen's programs are described in additional detail in Acumen's filings with the Securities and Exchange Commission ("SEC"), including in Acumen's most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.

Investors:
Alex Braun
abraun@acumenpharm.com

Media:
ICR Healthcare
AcumenPR@icrhealthcare.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ABOS
The Conversation (0)
Evotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases

Evotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases

Partnership will expand Evotec's molecular patient database in the area of metabolic diseases and in particular obesityEvotec will leverage its leading PanOmics technologies for the generation of large omics data sets including transcriptomics, proteomics and metabolomicsLille University... Keep Reading...

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in May 2024 Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024 Cash, cash equivalents and marketable... Keep Reading...

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C.... Keep Reading...

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 2024 Bank... Keep Reading...

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer's Disease

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the first patient has been dosed with sabirnetug... Keep Reading...
Why Gold, Silver and Critical Minerals Are Converging into One Compelling Investment Opportunity

Why Gold, Silver and Critical Minerals Are Converging into One Compelling Investment Opportunity

MiningNewsWire Editorial Coverage: Renewed safe-haven demand for gold and silver is building as U.S. debt climbs past 100% of GDP and central banks keep accumulating gold. At the same time, the federal 2025 List of Critical Minerals now covers silver, copper, lead and zinc, turning familiar... Keep Reading...
Transition Metals Advances Saturday Night with Deep-Penetrating Geophysics, Reports 2026 Summer Exploration Results

Transition Metals Advances Saturday Night with Deep-Penetrating Geophysics, Reports 2026 Summer Exploration Results

Key Highlights:Saturday Night: Coincident SPARTAN MT and gravity surveys underway, which look to improve subsurface geological interpretations and refine prospective drill targets.Gowganda: Mechanical stripping confirms structural and lithological trends associated with mineralization.Cryderman:... Keep Reading...
Metalsource Mining Moves to Unlock Byrd-Pilot Value Through Potential Spinout or Strategic Transaction

Metalsource Mining Moves to Unlock Byrd-Pilot Value Through Potential Spinout or Strategic Transaction

Strategic initiative aims to unlock shareholder value through Byrd-Pilot's copper-gold porphyry exploration potential while accelerating aggressive expansion drilling and larger stepouts at Silver Hill.Metalsource Mining Inc. (CSE: MSM) (OTCQB: MSMMF) (FSE: E9Z) ("Metalsource" or the "Company")... Keep Reading...
Questcorp Mining and Riverside Resources Commence Phase 2B Drilling at Luis Hill, La Union Project, Sonora, Mexico

Questcorp Mining and Riverside Resources Commence Phase 2B Drilling at Luis Hill, La Union Project, Sonora, Mexico

Questcorp Mining Inc. (CSE: QQQ) (OTCQB: QQCMF) (FSE: D910) (the "Company" or "Questcorp") and its joint venture partner and operator Riverside Resources Inc. ("Riverside") are pleased to announce the commencement of Phase 2B reverse circulation ("RC") drilling at the Luis Hill target at the La... Keep Reading...
Metalsource Mining Announces Management Transition as Silver Hill Exploration Advances

Metalsource Mining Announces Management Transition as Silver Hill Exploration Advances

Dale Moore continues to guide drilling operations as Tom Kleeberg transitions to a consulting role.Metalsource Mining Inc. (CSE: MSM) (OTCQB: MSMMF) (FSE: E9Z) ("Metalsource" or the "Company") announces a management transition that maintains continuity across its technical and operational teams... Keep Reading...
Steadright Begins Exploration at Péribonka Ree-Niobium Carbonatite Target in Quebec's Niobium District

Steadright Begins Exploration at Péribonka Ree-Niobium Carbonatite Target in Quebec's Niobium District

(TheNewswire) NSM CAPITAL SARL AMENDMENT APPROVED Muskoka, Ontario TheNewswire - November 12, 2026 Steadright Critical Minerals Inc. (CSE: SCM) ("Steadright" or "SCM") is pleased to announce that exploration is underway at the Péribonka Rare Earth Element (REE) and Niobium Carbonatite Target... Keep Reading...

Interactive Chart

Latest Press Releases

Related News